Shares of DexCom, Inc. (NASDAQ:DXCM – Get Free Report) have earned an average rating of “Moderate Buy” from the twenty brokerages that are covering the company, MarketBeat Ratings reports. Four ...
DexCom (NASDAQ:DXCM – Get Free Report) had its price objective increased by research analysts at Barclays from $90.00 to $93.00 in a report issued on Monday,Benzinga reports. The brokerage presently ...
BofA raised the firm’s price target on DexCom (DXCM) to $90 from $80 and keeps a Buy rating on the shares post the Q3 report. DexCom did a good job instilling confidence in its 2025 revenue target ...
On Monday, DexCom (NASDAQ:DXCM) shares received an optimistic update from Redburn-Atlantic, with analyst Issie Kirby (NYSE:KEX) upgrading the stock from Neutral to Buy and increasing the price target ...
Valued at a market cap of $29.6 billion, San Diego, California-based DexCom, Inc. (DXCM) is a medical device company specializing in designing, developing, and commercializing continuous glucose ...
DexCom, Inc.'s growth is impressive but limited by its niche market, with my projected ceiling being ~$7.5bn in peak annual revenues. Despite positive Q4 2024 results, DexCom's stock is fairly valued, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback